Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response-Reference-Cited by-同舟云学术

Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response

Published:2018-01 Issue:1 Volume:8 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Luo Xueping,Xu Zefeng,Li Bing,Qin Tiejun,Zhang Peihong,Zhang Hongli,Fang Liwei,Pan Lijuan,Hu Naibo,Qu Shiqiang,Zhang Yue,Huang Gang,Peter Gale Robert,Xiao Zhijian

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-017-0029-4.pdf

Reference26 articles.

1. Cervantes, F. et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood 113, 2895–2901 (2009).

2. Passamonti, F. et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115, 1703–1708 (2010).

3. Gangat, N. et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin. Oncol. 29, 392–397 (2011).

4. Cervantes, F. How I treat myelofibrosis. Blood 124, 2635–2642 (2014).

5. Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799–807 (2012).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM;Future Oncology;2024-07-29

3. Momelotinib in myelofibrosis;Expert Opinion on Pharmacotherapy;2024-03-23

4. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options;Expert Opinion on Investigational Drugs;2023-12-10

5. The management of myelofibrosis: A British Society for Haematology Guideline;British Journal of Haematology;2023-12